Scientific Article

Cardiopulmonary Bypass Using Argatroban as an Anticoagulant for a 6.0-kg Pediatric Patient

Address correspondence to: Brian Mejak, BS, CCP, Pediatric Perfusion, Doernbecher Children’s Hospital, Oregon Health & Science University, DCH8S, 3181 SW Sam Jackson Park Road, Portland, OR 97006. E-mail mejakb@ohsu.edu

Abstract

A patient was born with transposition of the great arteries, double-outlet right ventricle, interrupted aortic arch, and a ventricular septal defect and underwent a Damus–Kaye–Stansel procedure with a modified Blalock–Taussig shunt at 14 days old. Three months later, this patient presented with hypoxia and bradycardia was found to have a thrombus present in the main pulmonary artery extending to right pulmonary artery. After initiation of thrombolytic therapy, the patient became severely hypoxic and required the institution of extracorporeal membrane oxygenation. As the result of unknown heparin resistance independent of adequate antithrombin III levels, argatroban therapy was used to achieve desired anticoagulation. The patient was taken to the operating room and converted to conventional cardiopulmonary bypass once adequate activated clotting times were achieved using argatroban. This case report summarizes the use of argatroban as an anticoagulant for a 6.0-kg pediatric patient undergoing cardiopulmonary bypass.